JERSEY CITY, N.J., Aug. 29, 2023. Mitsubishi Tanabe Pharma America, Inc. today announced the presentation of positive results from the pivotal, Phase 3, multi-center, randomized, double-blind double-dummy (DBDD) BouNDless trial of investigational ND0612 – a continuous, 24 hours/day subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD) – as part of the International…Read More
Mitsubishi Tanabe Pharma America Presents Positive Results from Pivotal Phase 3 BouNDless Trial of Investigational ND0612 in People with Parkinsons Disease Experiencing Motor Fluctuations Drugscom MedNews
